Literature DB >> 29357016

New Developments in the Diagnosis, Therapy, and Monitoring of Eosinophilic Esophagitis.

Ronak Vashi Patel1, Ikuo Hirano2.   

Abstract

PURPOSE OF REVIEW: Eosinophilic esophagitis (EoE) has transformed over the past two decades from a little-known entity to a significant cause of morbidity in the adult and pediatric population. We reviewed the most recent advancements in the diagnosis, therapy, and long-term monitoring of EoE. RECENT
FINDINGS: Based on clinical, endoscopic, histologic, immunologic, and genetic similarities, there is growing consensus to move away from distinguishing proton pump inhibitor responsive esophageal eosinophilia as an entity distinct from EoE. An increasing number of studies have identified duration of untreated disease as an important determinant of esophageal stricture formation. New approaches to the empiric elimination diet including one, two, four, and step-up protocols were developed to reduce the need for repeated endoscopies during reintroduction of food triggers. Topical steroids remain the mainstay of medical therapy but newer formulations are under development to optimize esophageal delivery. Novel, disease activity monitoring techniques are being evaluated that assess esophageal inflammatory activity without the need for endoscopy. Understanding of EoE has increased remarkably from the first identification of the disease. The underlying pathogenesis continues to be explored leading to shifts in diagnostic criteria as well as novel therapeutic targets. Innovative methods to monitor disease are under investigation and more research is needed to understand the natural history of EoE.

Entities:  

Keywords:  Dysphagia; Eosinophil; Eosinophilic esophagitis; Esophagus; Gastroesophageal reflux disease

Year:  2018        PMID: 29357016      PMCID: PMC5843552          DOI: 10.1007/s11938-018-0167-1

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  60 in total

1.  Variable yield of allergy patch testing in children with eosinophilic esophagitis.

Authors:  Brenda Paquet; Philippe Bégin; Louis Paradis; Eric Drouin; Anne Des Roches
Journal:  J Allergy Clin Immunol       Date:  2012-12-20       Impact factor: 10.793

2.  High Prevalence of Response to Proton-pump Inhibitor Treatment in Children With Esophageal Eosinophilia.

Authors:  Carolina Gutiérrez-Junquera; Sonia Fernández-Fernández; M Luz Cilleruelo; Ana Rayo; Luis Echeverría; Sergio Quevedo; Teresa Bracamonte; Enriqueta Román
Journal:  J Pediatr Gastroenterol Nutr       Date:  2016-05       Impact factor: 2.839

3.  Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis.

Authors:  Evan S Dellon; David A Katzka; Margaret H Collins; Mohamed Hamdani; Sandeep K Gupta; Ikuo Hirano
Journal:  Gastroenterology       Date:  2016-11-23       Impact factor: 22.682

Review 4.  Distinguishing GERD from eosinophilic oesophagitis: concepts and controversies.

Authors:  Leila Kia; Ikuo Hirano
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2015-05-19       Impact factor: 46.802

Review 5.  Eosinophilic esophagitis: updated consensus recommendations for children and adults.

Authors:  Chris A Liacouras; Glenn T Furuta; Ikuo Hirano; Dan Atkins; Stephen E Attwood; Peter A Bonis; A Wesley Burks; Mirna Chehade; Margaret H Collins; Evan S Dellon; Ranjan Dohil; Gary W Falk; Nirmala Gonsalves; Sandeep K Gupta; David A Katzka; Alfredo J Lucendo; Jonathan E Markowitz; Richard J Noel; Robert D Odze; Philip E Putnam; Joel E Richter; Yvonne Romero; Eduardo Ruchelli; Hugh A Sampson; Alain Schoepfer; Nicholas J Shaheen; Scott H Sicherer; Stuart Spechler; Jonathan M Spergel; Alex Straumann; Barry K Wershil; Marc E Rothenberg; Seema S Aceves
Journal:  J Allergy Clin Immunol       Date:  2011-04-07       Impact factor: 10.793

6.  Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula.

Authors:  K J Kelly; A J Lazenby; P C Rowe; J H Yardley; J A Perman; H A Sampson
Journal:  Gastroenterology       Date:  1995-11       Impact factor: 22.682

7.  Health benefits and cost effectiveness of endoscopic and nonendoscopic cytosponge screening for Barrett's esophagus.

Authors:  Tatiana Benaglia; Linda D Sharples; Rebecca C Fitzgerald; Georgios Lyratzopoulos
Journal:  Gastroenterology       Date:  2012-10-03       Impact factor: 22.682

Review 8.  Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment.

Authors:  Glenn T Furuta; Chris A Liacouras; Margaret H Collins; Sandeep K Gupta; Chris Justinich; Phil E Putnam; Peter Bonis; Eric Hassall; Alex Straumann; Marc E Rothenberg
Journal:  Gastroenterology       Date:  2007-08-08       Impact factor: 22.682

9.  Functional luminal imaging probe topography: an improved method for characterizing esophageal distensibility in eosinophilic esophagitis.

Authors:  Zhiyue Lin; Peter J Kahrilas; Yinglian Xiao; Frédéric Nicodème; Nirmala Gonsalves; Ikuo Hirano; John E Pandolfino
Journal:  Therap Adv Gastroenterol       Date:  2013-03       Impact factor: 4.409

10.  Accuracy and Safety of the Cytosponge for Assessing Histologic Activity in Eosinophilic Esophagitis: A Two-Center Study.

Authors:  David A Katzka; Thomas C Smyrk; Jeffrey A Alexander; Debra M Geno; RoseMary A Beitia; Audrey O Chang; Nicholas J Shaheen; Rebecca C Fitzgerald; Evan S Dellon
Journal:  Am J Gastroenterol       Date:  2017-08-15       Impact factor: 10.864

View more
  3 in total

Review 1.  Strategy for Food Reintroduction Following Empiric Elimination and Elemental Dietary Therapy in the Treatment of Eosinophilic Gastrointestinal Disorders.

Authors:  Jill M Madison; Vrinda Bhardwaj; Melinda Braskett
Journal:  Curr Gastroenterol Rep       Date:  2020-03-28

2.  Eosinophilic esophagitis auxiliary diagnosis based on a peptide ligand to eosinophil cationic protein in esophageal mucus of pediatric patients.

Authors:  Tafarel Andrade de Souza; Ana Paula Carneiro; Andreia S Narciso; Cristina P Barros; Douglas Alexsander Alves; Luciane B Marson; Tatiane Tunala; Tânia M de Alcântara; Yara Cristina de Paiva Maia; Peter Briza; Fatima Ferreira; Luiz R Goulart
Journal:  Sci Rep       Date:  2022-07-18       Impact factor: 4.996

3.  Treatment-resistant eosinophilic oesophagitis successfully managed with tofacitinib.

Authors:  Lybil Briscia Mendoza Alvarez; Xiuli Liu; Sarah Glover
Journal:  BMJ Case Rep       Date:  2019-12-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.